Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
- Status
- RECRUITING
- Phase
- PHASE2
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
- Status
- RECRUITING
- Phase
- PHASE1
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE1
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
- Status
- WITHDRAWN
- Phase
- PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Status
- RECRUITING
- Phase
- PHASE1
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
- Status
- RECRUITING
- Phase
- PHASE2